With a market cap of $19.7 billion, Moderna, Inc. (MRNA) is a biotechnology company specializing in messenger RNA (mRNA) therapeutics, with operations in the United States, Europe and international markets. Its broad vaccine portfolio covers respiratory diseases (including COVID-19, RSV, influenza, and pandemic influenza), latent and enteric viruses, public health threats such as Zika and Mpox, and bacterial diseases such as Lyme disease.
Companies valued at $10 billion or more are generally considered “large-cap” stocks, and Moderna fits that criteria perfectly. Moderna also develops oncology therapies ranging from cancer vaccines to engineered T-cells, as well as treatments for rare diseases, including cystic fibrosis and metabolic disorders.
Shares of the Cambridge, Massachusetts-based company are down 9.7% from a 52-week high of $55.20. MRNA stock is up 97.9% over the past three months, outpacing the 1.3% increase in the broader Dow Jones Industrial Average ($DOWI) over the same time frame.
MRNA stock is up 69% on a YTD basis, outpacing the DOWI’s modest gains. Long-term, Moderna shares have gained 64.6% over the past 52 weeks, compared to the Dow Jones’ 12.3% return over the same time frame.
The stock has traded above the 50-day and 200-day moving averages since December 2025, showing an uptrend.
Moderna shares rose 5.3% on Feb. 13 after the company reported Q4 2025 revenue of $678 million, beating expectations, and a net loss of $826 million, down from a loss of $1.1 billion a year ago. Investors also reacted favorably to Moderna’s revised earnings growth of 10% through 2026, along with sharply reduced operating expenses, including a 31% year-over-year reduction in R&D spending in Q4.
This rally was further supported by pipeline progress, notably the full enrollment of a Phase 3 norovirus vaccine trial with data expected in 2026 and the full enrollment of a Phase 2 antisemiran autogenous bladder cancer trial.
In comparison, its rival Eli Lilly & Company ( LLY ) lags behind MRNA stock. LLY stock is down 6.2% on a YTD basis and has gained 8.4% over the past year.
